Trial Profile
A Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of TAK-385 10, 20, and 40 mg (p.o.) in the treatment of uterine fibroids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Relugolix (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors Takeda
- 09 May 2017 Results presented at the 65th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
- 07 May 2017 Results published in a Myovant Sciences Media Release.
- 07 May 2017 According to a Myovant Sciences media release, primary endpoint has been met. (Decrease in menstrual blood loss)